medigraphic.com
ISSN 1727-897X (Electronic)

2014, Number 1

<< Back Next >>

Medisur 2014; 12 (1)

Effectiveness of Increased Nuchal Translucency in Detecting Pregnancies at Risk for Chromosomal Abnormalities

González HL, Rodríguez RL, García RN, Valero AMP,Herrera MM, Jure RV

Language: Spanish
References: 25
Page: 63-76
PDF size: 253.81 Kb.


ABSTRACT

Background: assessment of embryonic anatomy by ultrasound since early ages leads to the detection of pregnancies at risk for chromosomal abnormalities. Advanced maternal age alone is not enough.
Objective: to assess the results of the nuchal translucency measurement at the first trimester ultrasound as a sonographic marker of chromosomal abnormalities.
Methods: a sample of 29 334 pregnant women was studied from September 2006 to December 2010. General performance of the sonographic marker was assessed taking into account the years and maternal age. Effectiveness of increased nuchal translucency in the indirect detection of chromosomal abnormalities was determined using the common parameters.
Results: the net number of increased nuchal translucencies diminished over the years, as well as the absolute amount of prenatal karyotypes performed; but its proportion increased along with the positive prenatal karyotypes among women with increased nuchal translucency. Among the 71 fetuses with increased translucency, seven cases of chromosomal abnormalities were confirmed by other elements of the prenatal program. The sensitivity of the isolated nuchal translucency was 14.6%; specificity was high (99.8%); positive and negative predictive values were 18.4% and 99.9%, respectively. Rates of false positives were very low.
Conclusions: high specificity reaffirms nuchal translucency as a good early marker of risk for chromosomal abnormalities, particularly Down syndrome and Trisomy 18, with a minimum rate of indications for invasive testing and an extra increase in the detection of fetal defects.


REFERENCES

  1. Oliva Rodríguez JA. Ultrasonografía. Diagnóstico fetal, obstétrico y ginecológico. La Habana: Editorial Ciencias Médicas; 2010.

  2. Muñoz-Cortés M, Arigita M, Falguera G, Seres A, Guix D, Baldrich E, et al. Contingent screening for Down syndrome completed in the first trimester: a multicenter study. Ultrasound Obstet Gynecol. 2012 ; 39 (4): 396-400.

  3. Szabo J, Gellen J. Nuchal fluid accumulation in trisomy 21, detected by vaginosonography in first trimester. Lancet. 1990 ; 336 (7823): 1133.

  4. Cheon MS, Shim KS, Kim SH, Hara A, Lubec G. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part IV). Amino Acids. 2003 ; 25 (1): 41-7.

  5. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011 ; 31 (1): 7-15.

  6. Schielen PC, Wildschut HI, Loeber JG. Down syndrome screening: determining the cutoff level of risk for invasive testing. Prenat Diagn. 2009 ; 29 (2): 190-2.

  7. Sun Q, Xu J, Hu SQ, Chen M, Ma RM, Lau TK, et al. Distribution and normal reference range of fetal nuchal translucency thickness in Kunming pregnant women in the first trimester. Zhonghua Fu Chan Ke Za Zhi. 2012 ; 47 (7): 514-7.

  8. Llanusa Ruiz C, Nodarse Rodríguez A, Enrique Vázquez Y, Carrillo Bermúdez L, Sánchez Lombana R. Valor de los marcadores epidemiológicos y sonográficos del primer trimestre como indicadores de riesgo de cromosomopatías. Rev Cub Ginecol Obstetr [revista en Internet]. 2009 [ cited 23 Ene 2012 ] ; 35 (4): [aprox. 10p]. Available from: http://bvs.sld.cu/revistas/gin/vol35_4_09/gin0940 9.htm.

  9. Domínguez Pérez ME, Luna Ceballos E, Núñez Portal A. Pesquisaje de trastornos cromosómicos mediante marcadores ultrasonográficos del primer trimestre. Rev Méd Electrón [revista en Internet]. 2006 [ cited 23 Ene 2012 ] ; 28 (4): [aprox. 10p]. Available from: http://www.revmatanzas.sld.cu/revista medica/ano 2006/vol4 2006/tema11.htm.

  10. Chasen ST, Sharma G, Kalish RB, Chervenak FA. First-trimester screening for aneuploidy with fetal nuchal translucency in a United States population. Ultrasound Obstet Gynecol. 2003 ; 22 (2): 149-51.

  11. Gasiorek-Wiens A, Tercanli S, Kozlowski P, Kossakiewicz A, Minderer S, Meyberg H, et al; German-Speaking Down Syndrome Screening Group. Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland. Ultrasound Obstet Gynecol. 2001 ; 18 (6): 645-8.

  12. Peuhkurinen S, Laitinen P, Honkasalo T, Ryynanen M, Marttala J. Comparison of combined, biochemical and nuchal translucency screening for Down syndrome in first trimester in Northern Finland. Acta Obstet Gynecol Scand. 2013 ; 92 (7): 769-74.

  13. van Heesch PN, de Rijke YB, Laudy JA, Wildschut HI. Erroneous production of PAPP-A kits: the impact of a downward shift in PAPP-A concentration on the test performance of first-trimester combined screening for Down syndrome. Prenat Diagn. 2011 ; 31 (8): 821-6.

  14. Ekelund CK, Petersen OB, Skibsted L, Kjaergaard S, Vogel I, Tabor A, et al; Danish Fetal Medicine Research Group. First trimester screening for Trisomy 21 in Denmark: implications on detection and birth rates of Trisomy 18 and Trisomy 13. Ultrasound Obstet Gynecol. 2011 ; 38 (2): 140-4.

  15. Dimitrova V, Markov D, Chernev T, Karagózova Zh, Mazneĭkova V, Andonova S, et al. Ultrasound screening for Down syndrome and other chromosomal abnormalities by fetal nuchal translucency measurement between 11-14 weeks of gestation. Akush Ginekol(Sofiia). 2005 ; 44 (1): 32-7.

  16. Jakobsen TR, Søgaar DK, Tabor A. Implications of a first trimester Down syndrome screening program on timing of malformation detection. Acta Obstet Gynecol Scand. 2011 ; 90 (7): 728-36.

  17. Salomon L, Porcher R, Socolov D, Lamrani H, Ville Y. Repeat measurements of nuchal translucency at 11-14  weeks of gestation: when do we need them?. Ultrasound Obstet Gynecol. 2013 ; 42 (6): 629-33.

  18. Peralta CF, Barini R. Obstetric ultrasound between the 11th and 14th weeks: beyond the screening for chromosomal abnormalities. Rev Bras Ginecol Obstet. 2011 ; 33 (1): 49-57.

  19. Besio C, Besio M. Consideraciones éticas del uso de la ultrasonografía 11-14 semanas como tamizaje de aneuploidías en la población chilena. Rev Chil Obstet Ginecol. 2009 ; 74 (1): 47-51.

  20. Evans M, Krantz D, Hallahan T, Sherwin J. Skewed to the left: Under measurement of NT’s and implications for screening efficiency. Am J Obstet Gynecol. 2009 ; 201 Suppl 6: S140.

  21. Evans MI, Krantz DA, Hallahan T, Sherwin J, Britt DW. Quality of nuchal translucency measurements correlates with broader aspects of program rigor and culture of excellence. Fetal Diagn Ther. 2013 ; 33 (4): 230-4.

  22. Bakker M, Mulder P, Birnie E, Bilardo CM. Intra-operator and inter-operator reliability of manual and semiautomated measurement of fetal nuchal translucency: a cross sectional study. Prenat Diagn. 2013 ; 30: 1-8.

  23. Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first-trimester: a study of Oriental, Asian and Afro-Caribbean populations. Prenat Diagn. 2005 ; 25 (5): 365-9.

  24. Hasegawa J, Nakamura M, Hamada S, Matsuoka R, Ichizuka K, Sekizawa A, Okai T. Distribution of nuchal translucency thickness in Japanese fetuses. J Obstet Gynaecol Res. 2013 ; 39 (4): 766-9.

  25. Morris JK, Savva GM. The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet A. 2008 ; 146 (7): 827-32.




2020     |     www.medigraphic.com